Disc Medicine fixed its FDA problem. Now it has to launch

The technology

Bitopertin is a once-daily pill that blocks GlyT1, a transporter that supplies glycine to developing red blood cells. Less glycine means less heme production and less of the toxic compound protoporphyrin IX (PPIX), which builds up in erythropoietic protoporphyria (EPP) and causes painful reactions to sunlight. Disc says bitopertin acts on the cause of disease rather than shielding the skin.

APOLLO tested the idea. In 183 patients, bitopertin lowered PPIX by 41.4% versus placebo and increased monthly pain-free time in light by 12.2 hours. Reactions to light also fell. The FDA's February objection was that earlier trials had not linked PPIX to sunlight outcomes, and APOLLO now shows both moving together.

The company is also building a hematology pipeline around iron biology. Selcodebart and DISC-3405 move hepcidin in opposite directions, with early data in myelofibrosis anemia and polycythemia vera.

The odds

The scientific risk is mostly cleared. The regulatory risk is not gone: the FDA's complete response letter said the earlier trials left uncertainty about whether PPIX predicts benefit. Disc and the FDA aligned in a Type A meeting that APOLLO, if successful, can serve as the basis for the response. Across the industry, 90.6% of filed drugs are approved, and 93.6% in rare disease, per BIO, Informa and QLS data for 2011 to 2020. A resubmission after a CRL is a special case, so those rates are background, not a forecast.

The mid-stage programs carry normal risk. Industry data put the chance of moving from phase 2 to phase 3 at 28.9%, and RESTORE-PV and RALLY-MF are uncontrolled studies with small subgroups.

The money

Disc priced 6.0 million shares at $75.00 in October, raising $450 million gross and about $422.4 million net. It also estimated $682.8 million of cash at Sept. 30. The company says that funds its plans into 2030, without bitopertin revenue. Before the raise, second-quarter net loss was $59.5 million, and a Hercules loan has $60.0 million drawn. The offering added about 16% to the share count of 38.3 million at June 30.

The risks

Regulatory timing comes first. Disc plans to resubmit by year-end and expects a decision by mid-2027, but any new FDA question could add time. Safety and tolerability come next: dizziness occurred in 50% of treated patients, mostly mild or moderate. The release did not give placebo rates. The third risk is commercial. EPP has one approved therapy, an implant, and a pill could change prescribing, but Disc still has to build a sales force for a rare-disease population. Fourth, the company is still loss-making, with a $59.5 million quarterly loss and a loan with a minimum cash covenant that begins testing on July 1, 2028 under the June amendment (8-K).

Our read

Disc did what a post-rejection company needs to do: it ran the trial the FDA asked for and hit every endpoint. The raise removes financing risk for years. What remains is whether the benefit is large enough, and the safety clean enough, for the FDA to approve on a broad label and for patients and doctors to switch. Full APOLLO data at a medical meeting, including baselines and placebo adverse events, will tell investors more than the topline did. The hematology pipeline is secondary today, but it matters over time: selcodebart expects FDA feedback by year-end, and DISC-3405 has a sickle cell dataset coming, so Disc could have several programs in discussion with regulators or investors during 2027 and is not dependent on bitopertin alone.